CHEK1 and ovarian carcinoma: As well as exhibiting single agent activity against TNBC and ovarian cancer cell lines, V158411 potentiated the cytotoxicity of chemotherapeutic drugs in these tumor types suggesting that Chk1 inhibitors either alone or in combination could be a viable treatment option in these tumor types.